Shayna Wagler
Psychiatric/Mental Health · Washington, INNPI 1700553781
Payments from drug & device makers
Across 153 payments — averaging $15.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$637
- Alkermes, Inc.$299
- Corium, LLC$208
- Teva Pharmaceuticals USA, Inc.$175
- Takeda Pharmaceuticals U.S.A., Inc.$151
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$149
- plus $692 from 12 others
What the payments were for
- Food & beverage$2,29599%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,311 in reported general payments places this provider in the 75th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 15 | $52,582 |
| Abilify MaintenaAripiprazole | 16 | $46,492 |
| Lurasidone Hcl | 25 | $22,970 |
| RexultiBrexpiprazole | 13 | $18,529 |
| Olanzapine OdtOlanzapine | 12 | $5,689 |
| Divalproex Sodium ErDivalproex Sodium | 38 | $5,157 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $4,790 |
| Naltrexone Hcl | 33 | $4,352 |
| LoxapineLoxapine Succinate | 13 | $3,658 |
| Doxepin Hcl | 25 | $2,891 |
| Divalproex Sodium | 24 | $2,768 |
| Quetiapine Fumarate | 87 | $2,682 |
| Ziprasidone Hcl | 42 | $2,344 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $2,142 |
| Trazodone Hcl | 100 | $2,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $117 | $65,02129 claims |
| Alkermes, Inc.Aristada | $299 | $52,58215 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $151 | $4,79013 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $175 | $3,65813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Washington
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
- Sharon ClevengerFort Wayne$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.